На этой странице перечислены больницы направления «Радиационная онкология» (включая Gallbladder Cancer Treatment) в Бангалор, Индия, включая Narayana Health, Manipal Hospitals, Medicover Hospital, Bangalore, Gleneagles Hospitals, Bengaluru и другие.
Спросите нас о «Gallbladder Cancer Treatment» в Бангалор, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 10 аккредитованных больниц (Радиационная онкология) в Бангалор, Индия
🇮🇳 Narayana Health
🇮🇳 Manipal Hospitals
🇮🇳 Medicover Hospital, Bangalore
🇮🇳 Gleneagles Hospitals, Bengaluru
🇮🇳 Manipal Hospital Malleshwaram (Northside)
🇮🇳 Manipal Hospital, Old Airport Road
🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)
🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)
🇮🇳 Apollo Hospital, Bannerghatta Road
🇮🇳 Fortis Hospital, Bannerghatta Road
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Радиационная онкология» указано среди её специализаций и она находится в Бангалор, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «gallbladder cancer treatment» в Бангалор, Индия?
Выбор подходящей больницы для «gallbladder cancer treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Радиационная онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Gallbladder Cancer Treatment»
Gallbladder cancer is a rare but aggressive malignancy requiring precise, multidisciplinary oncological care — from radical cholecystectomy and extended hepatic resection to adjuvant chemotherapy with gemcitabine-cisplatin regimens and targeted immunotherapy. With 5-year survival rates ranging from 15% to 80% depending on staging, early and expert intervention is critical. GAF Healthcare connects international patients with India's and the UAE's leading JCI- and NABH/DHA-accredited cancer centres, where high-volume hepatobiliary oncology teams deliver globally benchmarked outcomes at a fraction of Western costs.
Clinical Overview
Gallbladder cancer (GBC) is an epithelial malignancy arising from the mucosal lining of the gallbladder, with adenocarcinoma accounting for over 90% of cases. It is the most common biliary tract cancer globally, with disproportionately high incidence in South Asia, Latin America, and Eastern Europe. The gallbladder's thin walls and proximity to the liver (segment IV–V), bile ducts, portal vasculature, and regional lymphatics mean that even early-stage tumours can invade adjacent structures, making anatomical staging — using the AJCC/TNM 8th Edition classification — and radiological precision essential to treatment planning. Physiologically, the disease frequently presents late due to the gallbladder's lack of a serosal layer on its hepatic surface, allowing direct hepatic extension without peritoneal dissemination, and its rich lymphatic drainage accelerating nodal spread.
Подробнее →Who is a Candidate?
- ELIGIBLE FOR SURGICAL RESECTION:
- Histologically confirmed gallbladder carcinoma (adenocarcinoma, papillary, mucinous variants) staged T1b to T3 (AJCC 8th Edition)
- ECOG performance status 0–2
- Adequate hepatic reserve: future liver remnant (FLR) ≥30% of total functional liver volume (assessed by CT volumetry)
- No distant metastases (M0) on staging workup
- +22 more
Treatment Options & Approaches
Surgical APPROACHES:
1. SIMPLE CHOLECYSTECTOMY (T1a only): Acceptable for incidental T1a tumours confined to the lamina propria with clear margins on frozen section. Laparoscopic technique is standard. No re-resection required.
2. RADICAL CHOLECYSTECTOMY WITH HEPATIC RESECTION (T1b–T3, primary standard): En-bloc resection of the gallbladder with a 2–3 cm margin of hepatic parenchyma involving segments IVb and V. Accompanied by systematic lymphadenectomy of the hepatoduodenal ligament (portal hepatis), including pericholedochal, cystic duct, right hepatic artery, and anterior/posterior portal vein nodes (minimum 6 nodes for adequate staging). Bile duct excision with Roux-en-Y hepaticojejunostomy reconstruction is added when bile duct margin involvement is confirmed on frozen section or when achieving a clear cystic duct margin is not feasible.
3. EXTENDED HEPATIC RESECTION (T3–T4 with vascular or extensive hepatic involvement): Right hepatectomy or right trisectionectomy may be required for advanced local disease. Portal vein embolisation (PVE) is performed 4–6 weeks pre-operatively when FLR is inadequate (<30%). In selected centres, associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is employed.
Подробнее →Восстановление
PHASE 1 — PRE-TRAVEL WORKUP (2–4 weeks before departure):
- Patient submits medical records to GAF Healthcare case manager: histopathology, imaging (CT/MRI/PET-CT), blood reports, operative reports if prior cholecystectomy
- GAF connects patient with assigned hepatobiliary oncology team at chosen centre (India or UAE)
- Telemedicine consultation conducted: tumour board review, resectability assessment, staging confirmation, NGS report review
- Travel plan confirmed: visa category arranged (e-Medical Visa for India; visit/medical visa for UAE), treatment dates locked
- Insurance pre-authorisation initiated where applicable
PHASE 2 — ARRIVAL & PRE-OPERATIVE EVALUATION (Days 1–3 in-country):
Подробнее →Возможные риски
Gallbladder cancer surgery, particularly when involving extended hepatic resection and biliary reconstruction, carries a defined spectrum of perioperative and oncological risks that patients must understand before travel. Perioperative mortality at high-volume HPB centres ranges from 1–3% for standard radical cholecystectomy and up to 5–8% for major hepatectomy, with rates significantly lower at centres performing >20 hepatobiliary resections per month. The most significant surgical complication is post-hepatectomy liver failure (PHLF), graded using the ISGLS criteria, occurring in 5–10% of cases involving resection of >60% of hepatic parenchyma — mitigated by pre-operative FLR volumetry and portal vein embolisation when indicated. Bile leak (ISGLS Grade B/C) occurs in 5–15% of cases, typically managed conservatively with drain maintenance or radiological/endoscopic intervention. Post-operative haemorrhage requiring re-exploration occurs in 1–3% of patients. Hepaticojejunostomy anastomotic stricture is a delayed complication (6–24 months post-operatively) occurring in approximately 3–8% of reconstructed cases, managed with endoscopic balloon dilation or percutaneous interventions. Systemic chemotherapy with gemcitabine-cisplatin carries well-documented risks of myelosuppression (Grade 3/4 neutropaenia in 25–30%), nephrotoxicity (managed with vigorous pre-hydration), and peripheral neuropathy. Durvalumab and other checkpoint inhibitors carry immune-related adverse events (irAEs), including immune-mediated hepatitis (Grade ≥3 in 3–5%), colitis, and pneumonitis, requiring early recognition and corticosteroid management. Oncologically, even R0 resections carry substantial recurrence risk: approximately 60–70% of patients develop locoregional or distant recurrence within 2 years, emphasising the importance of structured adjuvant therapy and surveillance imaging (CT/MRI every 3–6 months for 2 years). Patients with bile spillage during prior laparoscopic cholecystectomy face elevated risk of peritoneal seeding; port-site excision is recommended and outcomes in this subgroup are generally poorer. GAF Healthcare ensures patients receive complete risk stratification, pre-operative optimisation, and written informed consent documentation from their treating HPB oncologist before committing to travel.
Почему GAF Healthcare
GAF Healthcare provides end-to-end non-medical coordination for gallbladder cancer patients travelling to India or the UAE, ensuring the treatment experience is seamless from the moment of enquiry to post-discharge follow-up.
Частые вопросы о процедуре «Gallbladder Cancer Treatment»
What is the cost of Gallbladder Cancer Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after Gallbladder Cancer Treatment?
What is the success rate of Gallbladder Cancer Treatment?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «gallbladder cancer treatment» в Бангалор, Индия
Найдите лучшие больницы для «gallbladder cancer treatment» в Бангалор, Индия
На этой странице представлено 10 больниц в Бангалор, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Gallbladder Cancer Treatment» в Бангалор, Индия
Сколько больниц направления «Радиационная онкология» представлено в Бангалор, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Бангалор, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Gallbladder Cancer Treatment» в Бангалор, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.